Track Fasenra price changes
Subscribe for DrugPrice updates by email. No spam, unsubscribe anytime.
Why Fasenra Costs $2,836.00 Per Claim
Fasenra (Benralizumab) is used to treat asthma/copd. According to CMS Medicare Part D spending data, the program spent $987.0M on this drug, covering 32,000 beneficiaries across 348,000 claims.
This drug is currently protected by patents expiring Nov 14, 2031. Until patent protection ends, no generic version can enter the market, which limits price competition. Once generics become available, the price typically drops 80-95%.
Spending on Fasenra increased by +18.6% year-over-year, driven by increased utilization among Medicare beneficiaries.
Price Breakdown
Drug Details
Frequently Asked Questions
Fasenra (Benralizumab) costs an average of $2,836.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $30,844.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.
Fasenra averages $2,836.00 per Medicare Part D claim — roughly equivalent to a 30-day supply for most patients on standard dosing. Without insurance, expect higher cash-pay prices unless you use a discount program (GoodRx, SingleCare, manufacturer copay assistance). With Medicare or commercial insurance, your out-of-pocket cost depends on your plan's formulary tier and deductible status.
A typical 30-day supply of Fasenra reflects in our Medicare Part D average of $2,836.00 per claim. No generic is available yet, so cost remains at brand-name pricing. Cash-pay prices vary by pharmacy — comparison shopping (or using GoodRx coupons) often saves 20-50% off the listed price.
Most commercial insurance plans and Medicare Part D plans cover Fasenra, but coverage varies by formulary tier. Fasenra is often Tier 2 or Tier 3 on most formularies, meaning a higher copay than generic alternatives. Some plans require prior authorization or step therapy. Check your plan's formulary or call the number on your insurance card to confirm.
Several options for cash-pay patients: (1) Manufacturer patient assistance programs — the manufacturer may offer copay cards or free-drug programs for income-qualified patients; (2) Discount programs like GoodRx, SingleCare, or RxSaver typically save 20-80% off the cash price; (3) Mark Cuban's Cost Plus Drugs offers transparent generic pricing if a generic is available; (4) 340B-eligible community health centers offer drugs at federally negotiated discounts. Patient assistance programs are the primary affordability path while no generic is available.
Fasenra is still under patent protection until Nov 14, 2031, giving the manufacturer market exclusivity. Once the patent expires, generics enter the market and prices typically fall 80-95% within 1-2 years.
No, Fasenra is currently brand-only. Patent protection expires Nov 14, 2031, after which generic versions may enter the market.
Medicare Part D spent $987.0M on Fasenra, covering 32,000 beneficiaries across 348,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.
Check manufacturer patient assistance programs for potential savings. You can also compare prices at different pharmacies, use prescription discount programs (GoodRx, SingleCare, Cost Plus Drugs), or ask your doctor about therapeutic alternatives in the same drug class.
Reading Fasenra's Medicare Pricing
Fasenra averages $2,836.00 per Part D claim — a high-cost brand medication, well above the commodity-generic range but below the specialty/biologic tier. A price in this band usually signals an on-patent brand with no generic equivalent, or a brand that holds share through prescriber and patient preference even where a generic exists. For asthma/copd, the gap between this price and a same-class alternative is where the real savings conversation tends to live.
Fasenra accounts for $987.0M in Medicare Part D spending — a large line item built from 348,000 claims across 32,000 beneficiaries. Whether that total is driven more by price or by volume is the useful question: a high $2,836.00 average claim cost means price is the lever, a modest one means utilization is. Either way, a drug at this spending level is firmly on plan formulary committees' radar.
No generic competes with Fasenra yet — patent protection runs to Nov 14, 2031, the date that matters most for its future price. Until then the savings levers are narrower: manufacturer copay assistance for those who qualify, discount-card pricing on cash-pay fills, and therapeutic substitution to a cheaper in-class option for asthma/copd where one exists. The structural price drop arrives with generic entry, which historically pulls prices down 80–95% within a year or two of the patent cliff.
Every figure here comes from the CMS Medicare Part D Drug Spending dashboard, which reports what the program paid — not the cash price at a retail pharmacy and not a patient's out-of-pocket cost. List prices also overstate the real economics: manufacturers pay confidential rebates to pharmacy benefit managers, so the net price plans actually pay is often well below the sticker. Treat $2,836.00 as a consistent Medicare-program benchmark for Fasenra, useful for comparing drugs on the same basis, rather than the price any one patient will see at the counter.
Related
Compare costs for other asthma/copd medications
Compare 10 drugs in the Asthma & COPD Inhalers class
See every AstraZeneca drug tracked by Medicare Part D
Top prescription drugs by Medicare spending
Drugs losing patent protection soon
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.